Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Given Consensus Rating of “Moderate Buy” by Brokerages

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has received an average rating of “Moderate Buy” from the six research firms that are covering the firm, Marketbeat Ratings reports. Three analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 1 year price target among analysts that have covered the stock in the last year is $10.40.

Separately, StockNews.com downgraded shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, November 12th.

Insiders Place Their Bets

In related news, CFO Sravan Kumar Emany sold 11,001 shares of the stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $4.08, for a total value of $44,884.08. Following the completion of the transaction, the chief financial officer now owns 309,572 shares of the company’s stock, valued at $1,263,053.76. This represents a 3.43 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 12.90% of the company’s stock.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

Several large investors have recently modified their holdings of the stock. KBC Group NV lifted its holdings in Ironwood Pharmaceuticals by 59.3% during the 3rd quarter. KBC Group NV now owns 8,593 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 3,198 shares during the last quarter. Wolverine Trading LLC bought a new position in shares of Ironwood Pharmaceuticals in the third quarter valued at approximately $51,000. Diversified Trust Co acquired a new position in shares of Ironwood Pharmaceuticals in the 3rd quarter worth approximately $52,000. Legacy Capital Group California Inc. bought a new stake in Ironwood Pharmaceuticals during the 3rd quarter worth approximately $59,000. Finally, First Dallas Securities Inc. acquired a new stake in Ironwood Pharmaceuticals during the 2nd quarter valued at $73,000.

Ironwood Pharmaceuticals Stock Up 0.7 %

Shares of NASDAQ:IRWD opened at $4.53 on Wednesday. The company has a market cap of $724.93 million, a price-to-earnings ratio of -151.00 and a beta of 0.34. The business has a 50 day moving average price of $4.04 and a 200 day moving average price of $4.77. Ironwood Pharmaceuticals has a twelve month low of $3.06 and a twelve month high of $15.70.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.07). Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%. The business had revenue of $91.60 million during the quarter, compared to the consensus estimate of $91.22 million. During the same period in the prior year, the company posted $0.12 earnings per share. The firm’s revenue was down 19.4% compared to the same quarter last year. Analysts anticipate that Ironwood Pharmaceuticals will post 0.08 EPS for the current year.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.